Michele Arcopinto1, Andrea Salzano, Jorgen Isgaard, Antonio Cittadini. 1. aDepartment of Cardiac Surgery, IRCCS Policlinico San Donato Milanese, Milan bDepartment of Translational Medical Sciences, Federico II University cInterdisciplinary Research Centre in Biomedical Materials (CRIB), University of Naples, Naples, Italy dDepartment of Internal Medicine, Sahlgrenska Academy, University of Göthenborg, Göthenborg, Sweden *Jorgen Isgaard and Antonio Cittadini contributed equally to the writing of this article.
Abstract
PURPOSE OF REVIEW: Despite major advances in medical treatments, survival rates of chronic heart failure (CHF) have not significantly changed in the past 50 years, making it imperative to search for novel pathophysiological mechanisms and therapeutic targets. In this article, we summarize the current knowledge regarding the possibility to treat such anabolic deficiencies with hormone replacement therapy (HRT). RECENT FINDINGS: Mounting evidence supports the concept that CHF is a disease characterized not only by excessive neurohormonal activation but also by a reduced anabolic drive that carries functional and prognostic significance. The recent demonstration of overall beneficial effects of HRT in CHF may pave the way to slow the disease progression in patients with coexisting CHF and hormone deficiencies. The hypothesis is to identify a considerable subset of CHF patients also affected with hormone deficiency and to treat them with HRT. SUMMARY: Single or multiple HRT may in theory be performed in CHF. Such a novel approach may improve left ventricular architecture, function, and physical capacity as well as quality of life. Larger randomized, controlled trials are needed to confirm this working hypothesis.
PURPOSE OF REVIEW: Despite major advances in medical treatments, survival rates of chronic heart failure (CHF) have not significantly changed in the past 50 years, making it imperative to search for novel pathophysiological mechanisms and therapeutic targets. In this article, we summarize the current knowledge regarding the possibility to treat such anabolic deficiencies with hormone replacement therapy (HRT). RECENT FINDINGS: Mounting evidence supports the concept that CHF is a disease characterized not only by excessive neurohormonal activation but also by a reduced anabolic drive that carries functional and prognostic significance. The recent demonstration of overall beneficial effects of HRT in CHF may pave the way to slow the disease progression in patients with coexisting CHF and hormone deficiencies. The hypothesis is to identify a considerable subset of CHFpatients also affected with hormone deficiency and to treat them with HRT. SUMMARY: Single or multiple HRT may in theory be performed in CHF. Such a novel approach may improve left ventricular architecture, function, and physical capacity as well as quality of life. Larger randomized, controlled trials are needed to confirm this working hypothesis.
Authors: Roberta D'Assante; Raffaele Napoli; Andrea Salzano; Carlotta Pozza; Alberto Maria Marra; Michele Arcopinto; Giuseppe Perruolo; Salvatore Milano; Pietro Formisano; Lavinia Saldamarco; Plinio Cirillo; Antonio Cittadini Journal: Endocrine Date: 2019-07-02 Impact factor: 3.633
Authors: Andrea Salzano; Roberta D'Assante; Liam M Heaney; Federica Monaco; Giuseppe Rengo; Pietro Valente; Daniela Pasquali; Eduardo Bossone; Daniele Gianfrilli; Andrea Lenzi; Antonio Cittadini; Alberto M Marra; Raffaele Napoli Journal: Endocrine Date: 2018-03-23 Impact factor: 3.633
Authors: E Bossone; M Arcopinto; M Iacoviello; V Triggiani; F Cacciatore; C Maiello; G Limongelli; D Masarone; F Perticone; A Sciacqua; P Perrone-Filardi; A Mancini; M Volterrani; O Vriz; R Castello; A Passantino; M Campo; P A Modesti; A De Giorgi; I Monte; A Puzzo; A Ballotta; L Caliendo; R D'Assante; A M Marra; A Salzano; T Suzuki; A Cittadini Journal: Intern Emerg Med Date: 2018-04-04 Impact factor: 3.397
Authors: M Arcopinto; A Salzano; F Ferrara; E Bobbio; A M Marra; R Abete; F Stagnaro; R Polizzi; F Giallauria; M Illario; E Menditto; C Vigorito; E Bossone; A Cittadini Journal: Transl Med UniSa Date: 2016-05-16
Authors: Michele Arcopinto; Andrea Salzano; Francesco Giallauria; Eduardo Bossone; Jörgen Isgaard; Alberto M Marra; Emanuele Bobbio; Olga Vriz; David N Åberg; Daniele Masarone; Amato De Paulis; Lavinia Saldamarco; Carlo Vigorito; Pietro Formisano; Massimo Niola; Francesco Perticone; Domenico Bonaduce; Luigi Saccà; Annamaria Colao; Antonio Cittadini Journal: PLoS One Date: 2017-01-17 Impact factor: 3.240
Authors: M Arcopinto; M Cataldi; V De Luca; V Orlando; G Simeone; R D'Assante; A Postiglione; A Guida; U Trama; M Illario; N Ferrara; E Coscioni; G Iaccarino; P Cuccaro; G D'Onofrio; C Vigorito; A Cittadini; E Menditto Journal: Transl Med UniSa Date: 2017-07-01
Authors: Andrea Salzano; Alberto M Marra; Michele Arcopinto; Roberta D'Assante; Vincenzo Triggiani; Enrico Coscioni; Daniela Pasquali; Giuseppe Rengo; Toru Suzuki; Eduardo Bossone; Antonio Cittadini Journal: ESC Heart Fail Date: 2019-11-07